Paysign (PAYS) The MicroCap Rodeo Conference - NYC summary

Business overview and history

• Operates as a program manager and processor, providing end-to-end payment solutions, primarily in healthcare and prepaid sectors.

• Headquartered in Southern Nevada, with over 20 years in payment services, especially for healthcare.

• Entered pharmaceutical prepaid space in 2007 and plasma industry in 2011, rebranding in 2019.

• Holds about 40% market share in U.S. plasma payments, serving 480 centers out of 1,200.

• Patient affordability (copay) programs are a significant and growing part of the business.

Financial performance and growth

• 2024 revenue reached $58 million, with trailing 12-month revenue at $64 million and adjusted EBITDA of $13 million.

• Gross margin improved to 62.9% in Q1, up from 53% year-over-year.

• Zero debt and $111 million in cash, with $7 million unrestricted.

• Patient affordability business projected to grow at least 135% in 2024, targeting $28–$30 million revenue.

• Plasma business expected to decline 8–10% in 2024 due to industry overcorrection but remains a cash cow.

Technology and operational highlights

• Proprietary Dynamic Business Rules technology saved customers over $100 million in 2024, with expectations to double savings in 2025.

• Cloud-based platform enables rapid software changes and high service uptime.

• Call center operates at breakeven, with fees covering operational costs.

• Revenue streams include cardholder fees, interchange, management fees, and claim fees.

• Leadership team brings deep expertise from banking, payments, and healthcare sectors.